A selection of our publications

Schwander B, Banz K, Kaier K, Walzer S. Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products. Health Policy 2014; 117: 334-44

Hancock-Howard RL, Feindel CM, Rodes-Cabau J, Webb JG, Thompson AK, Banz K. Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings. J Med Econ 2013; 16: 566-74

Ferreira González J, Serra V, Omar Abdul O, Paz S, Lizan L, Banz K et al. Evidencia del coste-efectividad de la implantación transcatéter de la prótesis valvular aórtica (TAVI) Edwards SAPIEN en pacientes de alto riesgo con estenosis aórtica sintomática en Espańa: resultados preliminaries. PharmacoEconomics - Spanish Research Articles 2013; 10: 1-13

Banz K, Welker C, Finsterwald D. Comparison of actual costs versus DRG revenue of cervical arthroplasty in patients with degenerative disc disease in Germany. Value Health 2012, 7; A352 (abstract PMD43)

Banz K, Harenski K, Brunner M et al. Preliminary cost-minimization analysis of continuous vs. intermittent renal replacement therapy in intensive care patients experiencing acute renal failure. Value Health 2011, (abstract PUK11)

Ferreira-González I, Serra V, Abdul O, Lizan L, Paz S, Banz K et al. Cost-effectiveness of transcatheter aortic valve implantation (TAVI) in high-risk or inoperable patients with symptomatic aortic valve stenosis in Spain. Value Health 2011, (abstract PMD25)

Banz K, Bischoff H, Brunner M et al. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer 2011; 74: 529-34

Chouaid C, Vergnenegre A, Brunner M, Walzer S. The cost of treating grade 3/4 adverse events related to first-line therapy with bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine for patients with advanced non-small cell lung cancer (NSCLC) in France. Value Health 2009, 12, A264 (abstract PCN43)

Heigener D, Bischoff HG, Banz K, Walzer S. Cost savings related to superior adverse event profile of bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine in the first-line therapy of advanced non-small cell lung cancer (NSCLC) in Germany: a sensitivity analysis on the ECOG status. Value Health 2009, 12, A265 (abstract PCN46)

Bischoff HG, Heigener D, Banz K, Walzer S. Costs of treating severe adverse events observed with a regimen of bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine in the first-line therapy of advanced non-small cell lung cancer (NSCLC) in Germany. Value Health 2009, 12, A265 (abstract PCN47)

Fagnani F, Litzler PY, Eltchaninoff H, Cribier A, Banz K. Cost-effectiveness of transcatheter aortic valve implantation in high-risk patients with symptomatic aortic valve stenosis in France. Value Health 2009, 12, A328 (abstract PCV86)

Banz K, Iseli A, Aebi C et al. Economic evaluation of varicella vaccination in Swiss children and adolescents. Human Vaccines 2009; 5: 847-57

Iseli A, Aebi C, Banz K et al. Prospective surveillance of varicella-zoster virus infections in an out-patient setting in Switzerland. Human Vaccines 2009; 5: 843-6

Morgan C, Wendler O, Banz K et al. What is the economic burden of disease for patients with aortic stenosis (AS) unable to undergo aortic valve replacement (AVR)? SCTS congress Bournemouth March 22-24, 2009 (abstract)

Bonanni P, Boccalini S, Bechini A, Banz K. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases. Vaccine 2008; 26: 5619-26

Marocco A, Bamfi F, Banz K et al. A cost-benefit analysis of different varicella vaccination strategies involving Italian children and adolescents. Value in Health 2006; 9: A299 (abstract). Presented at ISPOR Congress Copenhagen, October 2006

Forster J, Banz K, Heininger U et al. Krankheitslast durch Rotaviren und Effektivität einer Rotavirusimpfung in Deutschland: eine epidemiologische und ökonomische Analyse. Abstract P42b presented at DGPI Congress Munich, April 2006; 37

Banz K on behalf of the Eucomed CRT Steering Committee. Cardiac resynchronization therapy (CRT) in heart failure - A model to assess the economic value of this new medical technology. Value in Health 2005; 8 (2):128-39

Havrdova E, Banz K, Sharief M. Cost-benefit and cost-effectiveness of interferon beta-1 therapies for multiple sclerosis in the Czech Republic. Poster P186 presented at ECTRIMS Congress, Vienna, October 2004

Wagenpfeil S, Banz K, Wutzler P. Varizellenerkrankung: epidemiologische Aspekte und ökonomische Belastung. Wirtschaftlichkeit einer generellen Impfung. Kinderärztliche Praxis 2004; Sonderheft "Impfen": 28-33

Wagenpfeil S, Neiss A, Banz K, Wutzler P. Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect 2004; 10: 425-30

Hammerschmidt T, Wagenpfeil S, Neiss A, Wutzler P, Banz K. Einfluss der generellen Impfung von Kleinkindern gegen Varizellen auf die Budgets der gesetzlichen Krankenkassen in Deutschland. PharmacoEconomics - German Research Articles 2004; 2: 17-30

Banz K, Wagenpfeil S, Neiss A, Hammerschmidt T et al. The burden of varicella in Germany: Potential risks and economic impact. Eur J Health Economics 2004; 5: 46-53

Gras D, Banz K. Development and validation of a new decision-analytic model designed to evaluate the cost-effectiveness of cardiac resynchronisation therapy. ESC congress Vienna, 2003, abstract no. P2771

Hammerschmidt T, Goertz A, Wagenpfeil S, Neiss A, Wutzler P, Banz K. Validation of Health Economic Models: The Example of EVITA. Value in Health 2003; 5: 551-9

Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, Wutzler P. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003, 21; 1256-67

Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol. Immunol 2002; 191: 89-96

Duda SH, Feuls R, de Jong P, Greiner W; Pusich B, Banz K: Ökonomische Analysen in der Interventionellen Radiologie. Fortschr Röntgenstr 2002; 174: 149-59

Duda SH, Tepe G, Bala M, Luz O, Ziemer G, Ouriel K, Pusich B, Wiskirchen J, Claussen CD, Banz K. Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusion. PharmacoEconomics 2002; 20 (3): 203-13

Banz K, Klein W, Brunella A. The societal cost of atopic dermatitis in Germany. Value in Health 2001; 4 (6): 516 (Abstract)

Feuls R, Pusich B, Banz K, Greiner W, et al. Economical analyses in interventional radiology Radiology 2001; 221: 33 (Abstract)

Duda SH, Banz K, Ouriel K, Tepe G, Weissflog D et al: Is treatment of subacute peripheral artery occlusions with thrombolysis and adjunctive abciximab cost-effective? Cardiovasc. Intervent. Radiol. 2001; 24 (Suppl.): S183 (Abstract)

Wagenpfeil S, Neiss A, Görtz A, Bisanz H, Banz K, Wutzler P. Epidemiologische Studie zu Varizellen in Deutschland. DAE 2001; A14 (abstract)

Wutzler P, Neiss A, Banz K, Tischer A. Ist die Elimination der Varizellen durch eine allgemeine Impfung möglich? Epidemiologische und gesundheitsökonomische Daten als Basis für eine zukünftige Varizellen-Impfstrategie in Deutschland. Deutsches Ärzteblatt 2002; 15: C795-800

Goertz A, Banz K, Wagenpfeil S, Neiss A, et al. Can varicella be eliminated by universal childhood vaccination cost-beneficially? - Examples for Europe. Value in Health 2001; 4: 443 (abstract)

Duda SH, Banz K, Brehme U, Erley CM, Albes J, Tepe G, Wiskirchen J, Claussen CD. Cost-effectiveness analysis of treatment of renal artery stenoses by medication, angioplasty, stenting, and surgery. Min.Invas.Ther. & Allied Technol. 2001; 10: 55-65

Banz K, Staginnus U, Wagenpfeil S et al. Preliminary evaluation of the clinical and economic benefits of universal varicella vaccination of children in Germany. Value in Health 2000; 3 (5): 297 (Abstract)

Ikeda S, Bosch J, Banz K et al. Economic outcomes analysis of stenting versus percutaneous transluminal coronary angioplasty for patients with coronary artery disease in Japan. J Invas Cardiol 2000; 12: 194-9

Schneller P, Banz K, Staginnus U. Cost-effectiveness of combined hepatitis A and B vaccination and hepatitis B monovaccination in Switzerland and Austria. Value in Health 1999; 2 (5): 359 (Abstract)

Duda S, Banz K, Brehme U et al. Cost-effectiveness considerations for radiological and non-radiological treatment of renal artery stenoses CVIR 1999: S 94 (Abstract)

Banz K, Duda S, Tepe G. A decision-analytic model to analyse the cost-effectiveness of stent placement in patients with peripheral arterial disease. Intervention 1999; 4: 1-4

Duda S, Banz K, Brehme U et al. Kosten-Nutzen Analyse renaler Revaskularisationen mittels operativer und nicht-operativer Verfahren. Fortschr Röntgenstr 1999; 170: S101 (Abstract)

Banz K, Thomas A-M, et al. Economic evaluation of ribosomal immunotherapy in patients with chronic ear, nose and throat and respiratory tract infections. Results for Italy. BioDrugs 1998; 10 (5): 385-96

Banz K. Kosteneffektivität von PTCA vs. Bypass-Operation bei Patienten mit koronarer Mehrgefäßerkrankung: Ergebnisse einer Modellanalyse für Deutschland. ptca aktuell 1998; 11: 14-8

Banz K, Dinkel R, Hanefeld M, Schwanebeck U. Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. PharmacoEconomics 1998; 13 (4): 449-59

Serruys PW, Banz K, Darcis T, Mignot A, van Es G-A, Schwicker D. Results of a meta-analysis of trapidil, a PDGF inhibitor. A sufficient reason for a second look to the pharmacological approach to restenosis. J Invas Cardiol 1997; 9: 505-12

Banz K, Schwicker D. Cost-effectiveness of Palmaz-Schatz™ stenting for patients with coronary artery disease in Spain. J Invas Cardiol 1997; 9 (suppl. A): 41A-46A

Banz K, Schwicker D. Cost-effectiveness of Palmaz-Schatz™ stenting in patients with coronary artery disease in the Netherlands. J Invas Cardiol 1997; 9 (suppl. A): 35A-40A

Banz K, Schwicker D. Cost-effectiveness of Palmaz-Schatz™ stenting for patients with coronary artery disease in Italy. J Invas Cardiol 1997; 9 (suppl. A): 29A-34A

Banz K, Schwicker D. Cost-effectiveness of Palmaz-Schatz™ stenting in patients with coronary artery disease in Germany. J Invas Cardiol 1997; 9 (suppl. A): 23A-28A

Banz K, Schwicker D. Cost-effectiveness of Palmaz-Schatz™ stenting for patients with coronary artery disease in France. J Invas Cardiol 1997; 9 (suppl. A): 17A-22A

Schwicker D, Banz K. New perspectives on the cost-effectiveness of Palmaz-Schatz™ coronary stenting, balloon angioplasty, and coronary artery bypass surgery - A decision model analysis. J Invas Cardiol 1997; 9 (suppl. A): 7A-16A

Dinkel R, Banz K. Management of diabetes: Socioeconomic aspects. Medicographia 1995; 17 (2): 35-8

Banz K, Schwicker D. Kosten-Effektivität von Interferon-α-2a bei chronischer Virushepatitis. Medwelt 1994; 45: 320-6

Banz K, Schwicker D, Thomas A.M. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections. PharmacoEconomics1994; 6 (5): 464-77

Schwicker D, Banz K. Roferon®-A in chronic viral hepatitis. Treatment - Clinical Outcomes - Cost-Effectiveness. HealthEcon-Reihe: Gesundheit und Ökonomie, Band 6. Peter Lang, Bern, Frankfurt/M, New York, Paris, 1994

Banz K, Rohrbacher R, Schwicker D. Die Sozioökonomie der chronischen Lebererkrankungen in Deutschland. Epidemiologie - Diagnostik - Therapie - Kosten. HealthEcon-Reihe: Gesundheit und Ökonomie, Band 5. Peter Lang, Bern, Frankfurt/M, New York Paris, 1993

Dinkel R, Banz K, Büchner K, Steffen R, Gutzwiller F. Kosten/Nutzen-Analyse der Malariaprophylaxe bei Kenyareisenden mit Mefloquin. Sozial- und Präventivmedizin 1990; 35: 213-219